This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ponnazhagan, S. Articles by Meleth, S. Search for Related Content PubMed PubMed Citation Articles by Ponnazhagan, S. Articles by Meleth, S.

Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy

Long-Term Efficacy of a Vector Encoding Angiostatin and Endostatin over Vectors Encoding a Single Factor

Departments of ¹ Pathology and ² Medicine and the Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama

Angiogenesis is characteristic of solid tumor growth and a surrogate marker for metastasis in many human cancers. Inhibition of tumor angiogenesis using antiangiogenic drugs and gene transfer approaches has suggested the potential of this form of therapy in controlling tumor growth. However, for long-term tumor-free survival by antiangiogenic therapy, the factors controlling tumor neovasculature need to be systemically maintained at stable therapeutic levels. Here we show sustained expression of the antiangiogenic factors angiostatin and endostatin as secretory proteins by recombinant adeno-associated virus 2 (rAAV)-mediated gene transfer. Both vectors provided significant protective efficacy in a mouse tumor xenograft model. Stable transgene persistence and systemic levels of both angiostatin and endostatin were confirmed by in situ hybridization of the vector-injected tissues and by serum ELISA measurements, respectively. Whereas treatment with rAAV containing either endostatin or angiostatin alone resulted in moderate to significant protection, the combination of endostatin and angiostatin gene transfer from a single vector resulted in a complete protection. These data suggest that AAV-mediated long-term expression of both endostatin and angiostatin may have clinical utility against recurrence of cancers after primary therapies and may represent rational adjuvant therapies in combination with radiation or chemotherapy.

This article has been cited by other articles:

				C. Ren, S. Kumar, D. Chanda, J. Chen, J. D. Mountz, and S. Ponnazhagan Therapeutic Potential of Mesenchymal Stem Cells Producing Interferon-{alpha} in a Mouse Melanoma Lung Metastasis Model Stem Cells, September 1, 2008; 26(9): 2332 - 2338. [Abstract] [Full Text] [PDF]

				K. X. Cai, L. Y. Tse, C. Leung, P. K.H. Tam, R. Xu, and M. H. Sham Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin Clin. Cancer Res., February 1, 2008; 14(3): 939 - 949. [Abstract] [Full Text] [PDF]

				Z. Shen, Z. F. Yang, Y. Gao, J. C. Li, H. X. Chen, C. C. Liu, R. T.P. Poon, S. T. Fan, J. M. Luk, K. H. Sze, et al. The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma Cancer Res., January 15, 2008; 68(2): 404 - 414. [Abstract] [Full Text] [PDF]

				Y. Yokoyama, G. Sedgewick, and S. Ramakrishnan Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination Cancer Res., November 15, 2007; 67(22): 10813 - 10822. [Abstract] [Full Text] [PDF]

				T. Isayeva, D. Chanda, L. Kallman, I.-E. A. Eltoum, and S. Ponnazhagan Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model Cancer Res., June 15, 2007; 67(12): 5789 - 5797. [Abstract] [Full Text] [PDF]

				I. V. Subramanian, T. M. Bui Nguyen, A. M. Truskinovsky, J. Tolar, B. R. Blazar, and S. Ramakrishnan Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival. Cancer Res., April 15, 2006; 66(8): 4319 - 4328. [Abstract] [Full Text] [PDF]

				T. Isayeva, C. Ren, and S. Ponnazhagan Recombinant Adeno-Associated Virus 2-Mediated Antiangiogenic Prevention in a Mouse Model of Intraperitoneal Ovarian Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1342 - 1347. [Abstract] [Full Text] [PDF]